Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Britain Authorizes Johnson & Johnson’s COVID-19 Vaccine For Use

By John F. Heerdink, Jr.

Reportedly, Britain’s medicine regulator has approved Johnson & Johnson’s (JNJ) Janssen COVID-19 vaccine for use, making it the fourth COVID-19 vaccine to be approved in Britain. Britain had earlier approved vaccines made by Pfizer, AstraZeneca, and Moderna. The country reduced its order to 20 million doses from 30 million doses as the country’s vaccine rollout progresses. 

“This is very welcome news and another boost to our hugely successful vaccination programme,” Prime Minister Boris Johnson said on Twitter.

Britain has secured two-thirds of its adult population with the first COVID-19 shot, and the government cited the “unprecedented scale and pace” of the rollout as behind the decision to cut its order. However, Health Minister Matt Hancock stressed that the J&J shot would play a key role. 

J&J’s vaccine is already approved in the United States and European Union, where reports of rare blood clots are being assessed. The government said that the shots would be available later in the year. 

Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare-focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.

If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus. 

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.

(Read Original Story: UPDATE 2-Britain approves J&J COVID-19 vaccine, cuts order in Reuters)


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us